Erucamide molecule shows promise in slowing retinal degeneration

The retina doesn't simply wear away. It fights back. That's the insight emerging from a collaboration between Scripps Research, UC San Diego, and the Lowy Medical Research Institute—one that reframes how scientists think about the diseases that steal sight.

Retinal degeneration is the common thread running through many conditions that cause blindness: diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration. In each case, the light-sensing cells called photoreceptors begin to fail, and vision fades. Researchers have long understood the structural damage that accumulates, but the molecular conversations happening inside the retina as it responds to injury remained largely opaque. A team led by Martin Friedlander, a professor at Scripps Research, set out to decode those signals. Their discovery, published in Nature Neuroscience, centers on a naturally occurring molecule called erucamide—a compound that appears to orchestrate the retina's own defense against degeneration.

The work began with an intriguing observation. When researchers transplanted stem cell-derived retinal cells into damaged eyes, the cells slowed degeneration even after they had died and disappeared. This suggested the cells were releasing protective signals that outlasted their own survival. The question became: what were those signals? To find out, Friedlander's team used mass spectrometry-based metabolomics, a technique that measures thousands of small molecules in tissue simultaneously. They applied it to several established animal models of retinal disease, tracking which molecules changed as the disease progressed. Among the many compounds detected, erucamide stood out sharply. Its levels plummeted as photoreceptors began to deteriorate—a pattern that suggested the decline was not incidental but potentially causal.

The next step was to test whether restoring erucamide could actually slow the degenerative process. This presented a practical problem: erucamide is hydrophobic, meaning it doesn't dissolve well in water and tends to clump when injected. The team solved this by using porous silicon nanoparticles—tiny engineered vehicles designed to release molecules in a controlled manner. When they reintroduced erucamide into the eye using these delivery systems, something unexpected happened. The molecule didn't act directly on the photoreceptors themselves. Instead, it activated a group of immune cells in the retina called CD11b+ myeloid cells, which respond to injury and support tissue health. The researchers identified a protein called TMEM19 as the receptor through which erucamide communicates with these cells. When they reduced TMEM19 levels, the myeloid cells failed to activate and erucamide's protective effects disappeared.

Once stimulated, the myeloid cells released signals associated with neurovascular stabilization—supporting both the nerve cells and the blood vessels that nourish them. The effect wasn't a reversal of retinal damage, but it did slow aspects of degeneration by preserving the structure and function of the remaining tissue. This shift in perspective matters. Rather than trying to rescue dying photoreceptors directly, the approach strengthens the tissue's surrounding environment—the neurovascular unit that keeps the retina functioning. Guoqin Wei, the first author on the study who began this work seven years earlier as a postdoctoral researcher, notes that this indirect mechanism could prove important for how future therapies are designed.

But significant work remains before erucamide becomes a treatment. The hydrophobicity that makes the molecule biologically interesting also makes it difficult to formulate as a medicine, since most eye drugs are water-based. The team is working to improve delivery methods and testing modified versions of erucamide to see whether they produce stronger or more stable effects. They're also investigating whether related lipid molecules might be even more effective at activating the protective response. Future studies will need to clarify the full molecular pathway and test whether targeting this system provides meaningful benefits over time in various retinal diseases.

The broader implication is that some molecules already present in the body may be harnessed to support tissue under stress. Rather than introducing entirely foreign compounds, the strategy is to amplify signals the retina is already trying to send. As Friedlander puts it, the goal is to reinforce a response that's already there—to learn how to modulate it carefully so that it offers a new path for slowing retinal diseases where treatment options remain limited.